Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Neuro3d identifies candidate compound

The identification of this compound and extension of the research collaboration by J&JPRD further highlights the strength of Neuro3d's internal drug discovery capabilities.

21 Jul 2004

Cancer Research Technology grants exclusive license to Genentech to patent portfolio of an oncology target

Cancer Research Technology announced today that it has entered into a license agreement granting Genentech, Inc. exclusive worldwide rights to its patent portfolio covering an oncology target discovered in the Molecular Oncology Laboratory (Oxford) of Cancer Research UK.

21 Jul 2004

Natural products to be developed as anti-cancer therapeutics

The licence grants Zentaris exclusive worldwide rights for the development, manufacture and marketing of disorazoles, a novel class of natural products with strong anti-cancer potential discovered by GBF researchers.

8 Jul 2004

Exelixis files new drug application for a proprietary novel anticancer compound

Exelixis, Inc. has submitted an investigational new drug application (IND) to the U.S. Food and Drug Administration (FDA) for XL999, a proprietary novel anticancer compound.

29 Jun 2004

Drug for multiple sclerosis prevented disease development when tested on animal models

Scientists from the Neurological Sciences Institute at Oregon Health & Science University have shown that an investigative drug for multiple sclerosis and related diseases prevented disease development when tested on animal models.

20 Jun 2004

Outsourcing the way to control spiraling R&D budgets in drug industry

Companies developing new drugs for the global market must deal with the rising costs of the R&D process – and outsourcing may well be the best route. That's the verdict of Dr Faiz Kermani, a specialist in outsourcing and research development for the pharmaceutical industry.

14 Jun 2004

New statistical techniques for cancer diagnosis

CSIRO statisticians have developed a new way to subtype paediatric Acute Lymphoblastic Leukaemia (ALL), the most common form of cancer in children under 12.

9 Jun 2004

Australia's CSIRO to exhibit major display at the world's largest biotechnology conference

CSIRO is mounting a major display of technologies this week at BIO 2004, the world's largest biotechnology conference, being held in San Francisco, USA, from 6-9 June.

7 Jun 2004

Cystic Fibrosis Foundation Therapeutics awards $21 million to Vertex

Vertex Pharmaceuticals Incorporated has announced that it has expanded its drug discovery and development collaboration with Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation.

24 May 2004

Scientists have identified a compound that halts the activity of a deadly toxin called anthrax

University of Chicago scientists have identified a compound that halts the activity of a deadly toxin called anthrax lethal factor in laboratory tests. Nature Biotechnology will publish the findings online on May 16 and in the June issue of the journal's print edition.

17 May 2004

Publication of epilepsy research

Bionomics Limited has announced today that research by its collaborators Women's and Children's Hospital, in conjunction with the University of Melbourne and a US group in Tennessee, has been published in the scientific journal, Human Molecular Genetics.

13 May 2004

Ingenium's acquisition of US patents may lead to drug discovery and development

Ingenium Pharmaceuticals AG has acquired outright US patents no. 5,994,075 and no. 6,015,670 from Incyte Corporation, the company announced today.

12 May 2004

GenoMed adds to management team

GenoMed, Inc., a Next Generation Disease Management™ company that uses its expertise in genes to improve patient outcomes, said today that it has hired three additional full-time employees: a Chief Financial Officer, a Vice President for Marketing, and a Chief Technical Officer.

11 May 2004

Immtech signs agreement with CombinatoRx to test Immtech compounds as potential cancer treatment

Immtech International, Inc. announced today that it signed an agreement with CombinatoRx of Boston, Massachusetts to screen its lead aromatic cationic compounds, DB289 and DB75, for activity against various cancers.

5 May 2004

Functional genomics and proteomics may accelerate the discovery of new drugs and therapeutic molecules

Functional genomics and proteomics have been quite successful in identifying functions of potential therapeutic targets such as encoded proteins. In fact, the possibilities of identifying more than 10,000 novel target antigens in the human genome may accelerate the discovery of new drugs and therapeutic molecules.

29 Apr 2004

AGT Biosciences Limited and ChemGenex Therapeutics today announced merger agreement

AGT Biosciences Limited of Melbourne, Australia and privately held ChemGenex Therapeutics, Inc. of Menlo Park, California, today announced that they have signed a merger agreement. The cross-border merger creates a new, genomics-driven pharmaceutical company with leading edge capabilities for drug discovery and development, as well as two drug candidates in Phase II human trials for cancer.

28 Apr 2004

Inspire announces positive results in cystic fibrosis study

Inspire Pharmaceuticals, Inc. today announced top-line results in a Phase II study of INS37217 Respiratory in patients with mild cystic fibrosis (CF) lung disease.

27 Apr 2004

Spice turmeric corrects the cystic fibrosis defect

Scientists at The Hospital for Sick Children (Sick Kids) and Yale University School of Medicine have found that a compound in the spice turmeric corrects the cystic fibrosis defect in mice. This research is reported in the April 23, 2004 issue of the journal Science.

24 Apr 2004

Research into link between oceans and human health

The National Science Foundation (NSF) and the National Institute of Environmental Health Sciences (NIEHS), one of the National Institutes of Health, have announced funding for four joint Centers for Oceans and Human Health (COHH). The centers will be located at the University of Washington, the University of Hawaii, the Woods Hole Oceanographic Institution in Massachusetts, and the University of Miami.

22 Apr 2004

Clinical trial of curcumin in people with cystic fibrosis

Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation, today announced that it is funding a clinical trial of curcumin in people with cystic fibrosis (CF).

22 Apr 2004